El interés en corto de Lifevantage da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Lifevantage. Los datos de interés en corto se actualizan cada dos semanas.

Lifevantage (NASDAQ:LFVN) Bolsa, Informe de interés en corto

Lifevantage

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

LFVN

Descubre cómo dos acciones del sector de productos básicos alertan a inversores con altos valores de RSI este 2025.

2 acciones de productos básicos de consumo que podrían caer en el 1T

NAPA

PAVS

3 acciones sobrecompradas del sector de bienes de consumo con RSI sobre 70. ¿Son una señal de advertencia para inversores basados en impulso?

3 acciones sobrecompradas en bienes de consumo: ¿Oportunidad o advertencia?

Lifevantage Corp

WIIM

Lifevantage shares are trading lower following Q2 financial results.

<p><strong>Lifevantage</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.</p>
<p>Revenue was up $16.14 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at Lifevantage's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Earnings Breakdown: Lifevantage Q2

<p><strong>Lifevantage</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.</p>
<p>Revenue was up $16.14 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>In the previous quarter, the company missed on EPS by $0.0, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Lifevantage's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Lifevantage: Q2 Earnings Insights

<p><strong>Lifevantage</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported its Q2 earnings results on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.</p>
<p>Revenue was up $16.14 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at Lifevantage's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Lifevantage Q2 Earnings Assessment

<p>The earnings results for <strong>Lifevantage</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) for Q2 were made public on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.</p>
<p>Revenue was up $16.14 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Lifevantage's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Lifevantage Earnings Report: Q2 Overview

Lifevantage shares are trading lower. The company reported Q2 financial results.

<p>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) affirms FY2025 sales outlook from $235.00 million-245.00 million to $235.00 million-245.00 million vs $238.48 million estimate.</p>


Guidance

Lifevantage Affirms FY2025 Sales Guidance from $235.00M-245.00M to $235.00M-245.00M vs $238.48M Est

<p>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.13 by 69.23 percent. This is a 120 percent increase over earnings of $0.10 per share from the same period last year.  The company reported quarterly sales of $67.76 million which beat the analyst consensus estimate of $67.39 million by 0.55 percent.  This is a 31.26 percent increase over sales of $51.62 million the same period last year.</p>


Earnings Beats

Lifevantage Q2 Adj $0.22 Beats $0.13 Estimate, Sales $67.76M Beat $67.39M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<p><a href="https://www.globenewswire.com/Tracker?data=gwMH3B4Mtk6zsfMyNNHclGKg75ZpKpLzvyjPTOraiSWBqdNGO86iEObjelMlG7V3ynU183ZUCXrCrVdfwitv8WYas8qIx-n6vApENuMPv8eu0o5hC5I5R6eNYTC9FgG8BgC5gNw3LK74Tbqjpep5ZF64p7HSayWnDUrsVaj-kCpN3plEahB6rCmNAnaqTUTyG6ur--0jgBJH1oWZXTomxPIqsGNxYe8sOljRdf4RKeq639PT-lvEjkkvgVQZZ39CrDff_y2a9ske4V7QvFzvuMb4zeGNFJJHCX31TIjxQ_SIx3MgdM17XwjKQ9zJNx705vmVf9AO-_GNvvEoSicoc4suZDHS3bkoMcFAeCc31k1xcXTpnEfIllnHxx7EG67XEdaUOLS8jH9i3WcO-2MDDG5nYVeqvWTj7VWSeh5FYXrpa90Ot9IL145483aaQiUsavMmpoSeuLB11RNjVp-we0VJWGsLFPhhr7dMkkLfA6zCdlf7vgAmENB32mydv36vErBHSt6-fJCH2bB9EF-gEUnwqsyktuQ6JFbgdmp_m42uXMa445XN_NH-1ibQ9BOwl884Z9ehQ9MLwQVOn297kg==">LifeVantage Corporation</a><a href="https://www.globenewswire.com/Tracker?data=Asex0NnVLZW4-GgYGWwPWz1p1VgTONiNFv8H17XLaYyflNXPQy6eR1W-eEGy3EB731a-vldwrtIA-sIZsbHSYwh_2Cj9uBKRENRNS2QTWOymJSN_trhIboSnlx0dRgSWpHcEkteYxHqXh7_bN_WcnjCBqHZgg1YFs2tBcERBcm7l-QU9oPIlyHTSTJrmuMq3SWcnW2REk8QkpgdJVdvuLGk62Leyk-k4a3F7VUzc3mlxUwRksCGDNs3vDgI4tj1tJ4iFkJDtAfdHlRWqMCumQ68x7UdtJv0htEO9H9WDtOGndrmRHH0mDDjgj0QoIBvUUfG2TFRjXQiv5loebBxlXR74ls5j11XY2wCU4hUuEhgLSoqYVts3VALscCwNuZ6beqQd0jR5BY55EVeFkvFx9n2BcNQPfD8dsl0Ak-Ec0G6N46_pTKuuTX1424i1W2h5MdhVXIlBZxBJLLqM-ipLhQTUv5xIAKWWAtg94Dcu6hO7R0jN7AjAtr5yzc5fiacmi3qGS_twKqKPNF_7XxkAJNRBRS3ICyQNy6iN9uzf0WU=">&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the completion of an international <i>in vitro</i> cell study that investigated the effects of its international formulation for the <a href="https://www.globenewswire.com/Tracker?data=4RuCMkUyZ8cIhcCPRa6OUEHlQxhJ9T8Ko5KBDl48fq56IrkMD1d3V_QN4szyzBJTG7-0pdp1kq_kIBH2kRe9Hm8lIXFtkyOZnzCRl80VIaowXYDcN0VuxQnKnPRIv-e7VNdDCTe8mmt8EQnkjOii6C-YAWasQpKvB2F2O3p5dMXJ76BkszdYtlZ7xn3NmCKHLM8hwjbtQrzfQijH2ReKDTe5bfgSygkObOc96IoCg1FCsZCZBz4Ve703EInxU55RS7ghp7gF8Uph_GAK1HnIQnKR0S_P7iUiE3DDJGgAWnYOMnq_UYCWpyhqdvUYonJ9UXmliBGEZq6JKunRrmuavsr559roSLs4XTagYXDgC0BpNMa4FEqgdeXObi2Rv_sEiIEZ3GsivMbfNPOusejDXMEE1FaJdANyVLJnU1NVs_C6AUSPjdA6nxO_TvvEAnAdoah59lqrk0FHVsI87sga2Z-O1ChL4vXOz3PiX_Qe7zqGAueQJ7nGwyMM3EufYzE3RX3xWVuz4aKNHDAJeE20347lqyPAvcflQjLjIBKUJ-Uy_IxD_2y7ZIBZjoJh1RnCS6nohML2f2UWM_G0UQhJbt0DZc4XrUyiwwX71i-yDaeb1DfvL6qlEgUUrjIvnvaK">MindBody GLP-1 System&#x2122;</a>, known as the MB System&#x2122;, on activating GLP-1 production.&#x2A;&nbsp;</p>
<p>The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.</p>
<p>Key genes involved in the production and regulation of GLP-1 and associated neuropeptides were thoroughly examined, including:&nbsp;<br /><br />&nbsp;</p>
<ul>
<li><strong>GCG:</strong> Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis.&nbsp;</li>
<li><strong>GLP1R:</strong> Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity.&nbsp;</li>
<li><strong>DPP-4:</strong> An enzyme that degrades GLP-1, reducing the amount available in the body.&nbsp;</li>
<li><strong>PYY and PPY:</strong> Support the production of neuropeptides that work with GLP-1 along the gut-brain axis to regulate hunger signals.&nbsp;</li>
</ul>
<p>The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body's GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of five naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches.&#x2A;&nbsp;</p>


Biotech

General

LifeVantage Announces Completion Of Study On MindBody GLP-1 System. The Study Focused On L-Cells And Key Genes In GLP-1 Production Using ELISA And Fluorescent Microscopy

<p>Craig-Hallum  analyst Alex Fuhrman   initiates coverage on Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) with a Buy rating and announces Price Target of $35.</p>


Price Target

Initiation

Analyst Ratings

Craig-Hallum Initiates Coverage On Lifevantage with Buy Rating, Announces Price Target of $35

<p><a href="https://www.globenewswire.com/Tracker?data=QICvUiLZeNOvfe6ZTx3s27EQ7dD4hI1hClQPV-1-39rw6P62jWvuIrW4UxkYTXClcz7J-fwcSeSdnMQ8PawaVS1kUy8179zk86G4Y9n1aQmPAiJIYp97pioLnz-4DRAYIKqDhaUUsApLUJcvIEEtf07Nf4OUrPMYeKbjXDZdg6SIU2YsU35AQzXZuCEzGjjbGABFxNCakcCUSfaFSrOHvwjxtV_OUM95u6okwf9QYB2mEwT72CqzhsFw1Fkei8DP8yQsiwQOBdgJzJM0VikYwZk5YrTAxXTX8M0CskikgaUJMJmlt9QYhmaby8-JAoJamtTZbIDZXqrgqFJFxq8fSCBg1IVanYMF6PcHImSICrEPk2VJIEDTBlBF6npaQdEEiHTPj1OCtMk0M961fU1AMfbWvTAxMA9Js2nZYl7iocjuWPfz4lusSv1kZUirQZw9DvbfYtu46-aw1e1HSpLpvpJnnSyL1BM6Z0FzWjt9G9N584A-suNw7j4WGhTVFRrG__JKKt-D5Sm2BrQSIN605sWLqGFyFahNJ9_hag8eIcY9Y3vlEzOe1JoQzuXwQatZBFlcJqRvTBFtKTT6oB7n1A==">LifeVantage Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, hosted its annual Global Kickoff on Saturday, January 11, 2025. Thousands of the company's independent Consultants around the world joined the live broadcast to celebrate the company's bold vision for 2025, which emphasized momentum, continued innovation, and international expansion of the MindBody GLP-1 System&#x2122;. The company also announced that the Philippines, Taiwan, Hong Kong, and Singapore markets will transition to the Evolve Compensation Plan on March 1, with Thailand, the final market to move to Evolve, planned for transition by the end of the fiscal year.</p>
<p>An energetic tone was set early in the broadcast by President and CEO Steve Fife, who introduced the 2025 theme: "Drive ERA." The theme's core message encourages Consultants to build on the momentum of the previous year, find their internal motivations, and take proactive control of their success.</p>


Global

LifeVantage Announces 2025 Vision At Global Kickoff, Emphasizes MindBody GLP-1 System Expansion, Philippines, Taiwan, Hong Kong, Singapore To Transition To Evolve Plan On March 1, Thailand By Fiscal Year End

LifeVantage shares are trading higher after the company reported preliminary Q2 revenue and raised its FY25 revenue guidance.

LifeVantage Reports Preliminary Q2 Revenue of $67.5M vs $51.45, Up 31% YoY and 43% Sequentially, Raises FY25 Revenue Guidance to $235M-$245M vs Prior $200M-$210M (Est. $204.3M)

<p>As of Jan. 6, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Oil-Dri Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>)</strong></h3>
<ul>
<li>On Dec. 9, Oil-Dri reported a year-over-year increase in first-quarter financial results. Daniel S. Jaffee, President and Chief Executive Officer, stated, &#8220;I am happy to report that our fiscal year 2025 is off to a very positive start as we have once again achieved record results for consolidated net sales, gross profit, and net income in the first quarter." The company's stock surged around 29% over the past month and has a <a href="https://www.benzinga.com/quote/ODC">52-week high of $93.00</a>.</li>
<li><strong>RSI Value:</strong> 91.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>ODC Price Action:</strong> Shares of Oil-Dri Corporation of America fell 48.9% to close at $43.78 on Friday.</li>
</ul>
<h3 class="wp-block-heading"><strong>LifeVantage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>)</strong></h3>
<ul>
<li>On Dec. 19, Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26. The company's stock gained around 22% over the past month and <a href="https://www.benzinga.com/quote/LFVN">has a 52-week high</a> of $19.06.</li>
<li><strong>RSI Value:</strong> 70.4</li>
<li><strong>LFVN Price Action:</strong> Shares of LifeVantage gained 0.7% to close at $17.79 on Friday.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42810054/this-analyst-with-85-accuracy-rate-sees-around-16-downside-in-tesla-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></strong></li>
</ul>


Top 2 Defensive Stocks That May Crash In Q1

<p>As of Dec. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Paranovus Entertainment Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>)</strong></h3>
<ul>
<li>On Sept. 13, Paranovus Entertainment Technology filed for offering of 60 million Class A ordinary shares offered by selling shareholders. The company has a <a href="https://www.benzinga.com/quote/PAVS">52-week high of $2.97</a>.</li>
<li><strong>RSI Value:</strong> 84.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>PAVS Price Action:</strong> Shares of Paranovus Entertainment gained 1.4% to close at $1.42 on Thursday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Duckhorn Portfolio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>)</strong></h3>
<ul>
<li>On Dec. 5, Duckhorn Portfolio posted in-line quarterly earnings. &#8220;We are pleased to begin fiscal 2025 with strong financial performance. Our growth continues to outpace the industry as our teams remain focused on advancing our strategic initiatives,&#8221; said Deirdre Mahlan, President, CEO and Chairperson. &#8220;We believe our distinctive brands, operational excellence and market-leading performance leave us well positioned to deliver long-term growth and profitability.&#8221; The company's stock gained around 48% over the past six months and <a href="https://www.benzinga.com/quote/NAPA">has a 52-week high</a> of $11.10.</li>
<li><strong>RSI Value:</strong> 76.78</li>
<li><strong>NAPA Price Action:</strong> Shares of Duckhorn Portfolio climbed 0.1% to close at $11.09 on Thursday.</li>
</ul>
<h3 class="wp-block-heading"><strong>LifeVantage Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>)</h3>
<ul>
<li>On Dec. 19, Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26. The company's stock gained around 37% over the past month and has a <a href="https://www.benzinga.com/quote/LFVN">52-week high</a> of $18.41.</li>
<li><strong>RSI Value:</strong> 71.65</li>
<li><strong>LFVN Price Action:</strong> Shares of LifeVantage jumped 15.5% to close at $17.73 on Thursday.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a></strong></li>
</ul>


Top 3 Risk Off Stocks That May Collapse This Month

Lifevantage shares are trading higher after Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26.

<p>Lake Street  analyst Brooks O'Neil   initiates coverage on Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) with a Buy rating and announces Price Target of $26.</p>


Lake Street Initiates Coverage On Lifevantage with Buy Rating, Announces Price Target of $26

<p><a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a></p>


AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

TERN

VANI

VKTX

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

<p><a href="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf" title="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf">https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf</a></p>


'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – TTM Technologies&nbsp;(TTMI)&...

Closing Bell Movers: Semis down sharply after results

LifeVantage anticipates 25% growth in Americas active accounts with MindBody system expansion

LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript

Lake Street Keeps Their Buy Rating on LifeVantage (LFVN)

Craig-Hallum analyst Alex Fuhrman maintained a Buy rating on LifeVantage (LFVN – Research Report) today. The company's shares closed yesterday at $...

Craig-Hallum Sticks to Their Buy Rating for LifeVantage (LFVN)

09:32 EST Lifevantage (LFVN) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving ...

Lifevantage trading halted, volatility trading pause

09:37 EST Lifevantage (LFVN) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Lifevantage trading resumes

LifeVantage: Post-Earnings Selloff Provides Buying Opportunity

LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity

LifeVantage Corp (($LFVN)) has held its Q2 earnings call. Read on for the main highlights of the call. LifeVantage Corporation's recent earnings ca...

LifeVantage Earnings Call Highlights Growth and Challenges

KURA

QCOM

RAMP

TTMI

Press Releases

LifeVantage to Participate in the 27th Annual ICR Conference

LifeVantage Announces Preliminary Second Quarter Revenue Results and Raises Fiscal 2025 Revenue Guidance

Health Care

LifeVantage Study Confirms Breakthrough Synergistic Effects of Healthy Weight Stack*

LifeVantage Launches 2025 Vision with "Drive ERA" Theme and International Expansion Plans for Evolve Compensation Plan and the MindBody GLP-1 System™

Management

LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

TrueScience® Activated Skincare Collection Recognized for Cutting-Edge Innovation, Clean Beauty Standards, and Proven Anti-Aging Results*

LifeVantage to Announce Second Quarter Fiscal Year 2025 Results on February 5, 2025

LifeVantage Announces Completion of International In Vitro Study on the MB System™

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2025

Dividends

LifeVantage Declares Quarterly Dividend

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Craig-Hallum

Lake Street

Comments

Lifevantage

Interés en corto

Lifevantage (NASDAQ:LFVN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL